Mount Sinai researchers have conducted one of the first studies to show the acute effect of obstructive sleep apnea on Alzheimer’s disease biomarkers, and the ability to even measure Alzheimer’s disease biomarkers from blood.
As human lifespans increase, new societal challenges arise. In a “superaging society,” in which young people are few and older people are many, caring for the older adult population adequately with limited resources is a difficult balancing act to perform.
Two new studies offer insights into the factors that may contribute to the disproportionate burden of dementia in non-White and low-income U.S. populations.
UNDER EMBARGO UNTIL 11am EST on August 24: Cell Reports Senior Author: Paul A. Slesinger, PhD, Lillian and Henry M. Stratton Professor of Neuroscience and Director of the Center for Neurotechnology and Behavior, Icahn School of Medicine at Mount Sinai,…
UT Southwestern researchers have identified an immune protein tied to the rare neurodegenerative condition known as Niemann-Pick disease type C. The finding, made in mouse models and published online in Nature, could offer a powerful new therapeutic target for Niemann-Pick disease type C, a condition that was identified more than a century ago but still lacks effective treatments.
Article title: Early functional changes associated with alpha-synuclein proteinopathy in engineered human neural networks Authors: Vibeke D. Valderhaug, Kristine Heiney, Ola Huse Ramstad, Geir Bråthen, Wei-Li Kuan, Stefano Nichele, Axel Sandvig, Ioanna Sandvig From the authors: “In this study, we investigate the…
The interaction between an individual’s genetics and their local environment plays a critical role in an individual’s likelihood of getting Parkinson’s disease. In this perspective, researchers highlight how a common fly could be used to better understand the complex interactions…
The 2021 Virtual ACSM Basic Science World Congress focuses on regenerative medicine. Chaired by Marcas M. Bamman, Ph.D., FACSM, from the University of Alabama at Birmingham, this world congress brings together researchers to discuss cutting-edge science in this rapidly developing field.
By capitalizing on a convergence of chemical, biological and artificial intelligence advances, scientists have developed an unusually fast and efficient method for discovering tiny antibody fragments with big potential for development into therapeutics against deadly diseases.
Researchers have identified a family of enzymes whose inhibition both protects neurons and encourages their growth, a pathway to potential new treatments for neurodegenerative diseases from Alzheimer’s to glaucoma.
Findings offer potential target for treating behavioral abnormalities associated with neurodegenerative conditions like Alzheimer’s Disease
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons. The National Institutes of Health (NIH)-funded lab has produced the first pathoconnectome, showing how eye disease alters retinal circuitry.
Even mild concussions cause severe and long-lasting impairments in the brain’s ability to clean itself, and this may seed it for Alzheimer’s, dementia and other neurodegenerative problems.
Researchers in Japan have identified a new quality control system that allows cells to remove damaged and potentially toxic proteins from their surroundings. The study, which will be published February 18 in the Journal of Cell Biology, finds that the Clusterin protein and heparan sulfate proteoglycans combine to bring misfolded proteins into cells for degradation. The findings may lead to new therapeutic targets for neurodegenerative disorders, including Alzheimer’s disease.